The New Drug Application (NDA) is the vehicle in the United States The United States of America is a federal constitutional republic comprising fifty states and a federal district. The country is situated mostly in central North America, where its forty-eight contiguous states and Washington, D.C., the capital district, lie between the Pacific and Atlantic Oceans, bordered by Canada to the north and Mexico to the through which drug sponsors formally propose that the FDA The Food and Drug Administration is an agency of the United States Department of Health and Human Services and is responsible for regulating and supervising the safety of foods, dietary supplements, drugs, vaccines, biological medical products, blood products, medical devices, radiation-emitting devices, veterinary products, and cosmetics. The FDA approve a new pharmaceutical for sale and marketing. The goals of the NDA are to provide enough information to permit FDA reviewers to establish the following:
- Is the drug Many natural substances such as beers, wines, and some mushrooms, blur the line between food and drugs, as when ingested they affect the functioning of both mind and body safe and effective in its proposed use(s) when used as directed, and do the benefits of the drug outweigh the risks?
- Is the drug’s proposed labeling (package insert A package insert or prescribing information is a document provided along with a prescription medication to provide additional information about that drug) appropriate, and what should it contain?
- Are the methods used in manufacturing (Good Manufacturing Practice Good Manufacturing Practice or GMP is a term that is recognized worldwide for the control and management of manufacturing and quality control testing of foods, pharmaceutical products, and medical devices, GMP) the drug and the controls used to maintain the drug’s quality adequate to preserve the drug’s identity, strength, quality, and purity?
Contents |
Before trials
To legally test the drug on human subjects in the U.S., the maker must first obtain an Investigational New Drug The United States Food and Drug Administration's Investigational New Drug program is the means by which a pharmaceutical company obtains permission to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved. The FDA reviews the IND application for safety to (IND) designation from FDA. This application is based on pre-clinical data, typically from animal studies, that shows the drug is safe enough to be tested in humans.
Often the "new" drugs that are submitted are not new molecular entities, but old medications that have been modified.
Clinical trials
The legal requirement for approval is "substantial" evidence of efficacy demonstrated through controlled clinical trials In medical research, clinical trials are conducted to allow safety and efficacy data to be collected for new drugs or devices. These trials can only take place once satisfactory information has been gathered on the quality of the product and its non-clinical safety, and Health Authority/Ethics Committee approval is granted in the country where the. [1] This standard lies at the heart of the regulatory program for drugs. It means that the clinical experience of doctors, the opinion of experts, or testimonials from patients, even if they have experienced a miraculous recovery, have minimal weight in this process. Data for the submission must come from rigorous clinical trials.
The trials are typically conducted in three phases:
- Phase 1: The drug is tested in a few healthy volunteers to determine if it is acutely toxic.
- Phase 2: Various doses of the drug are tried to determine how much to give to patients.
- Phase 3: The drug is typically tested in double-blind The blind method is a part of the scientific method, used to prevent research outcomes from being influenced by either the placebo effect or the observer bias. To blind a person involved in research is to prevent them from knowing certain information about the process. The terms 'blind' (adj) or 'to blind' (vt) when used in this sense are, placebo A placebo is a sham medical intervention intended to lead the recipient to believe that it may improve his/her condition. In one common placebo procedure, a patient is given an inert sugar pill, told that it may improve his/her condition, but not told that it is in fact inert. Such an intervention may cause the patient to believe the treatment controlled trials to demonstrate that it works. Sponsors typically confer with FDA prior to starting these trials to determine what data is needed, since these trials often involve hundreds of patients and are very expensive.
- (Phase 4): These are post-approval trials that are sometimes a condition attached by the FDA to the approval.
The legal requirements for safety and efficacy have been interpreted as requiring scientific evidence that the benefits of a drug outweigh the risks and that adequate instructions exist for use, since many drugs are toxic and technically not "safe" in the usual sense.
Many approved medications for serious illnesses (i.e. cancer) have severe and even life-threatening side effects. Even relatively safe and well understood OTC drugs such as aspirin Aspirin , also known as acetylsalicylic acid (pronounced /əˌsɛtɪlsælɪˌsɪlɪk ˈæsɪd/, abbreviated ASA), is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication can be dangerous if used incorrectly.
The actual application
The results of the testing program are codified in an FDA-approved public document that is called the product label, package insert or Full Prescribing Information. [2]The prescribing information is widely available on the web, from the FDA, [3]drug manufacturers, and frequently inserted into drug packages.The main purpose of a drug label is to provide doctors with adequate information and directions for the safe use of the drug.
The documentation required in an NDA is supposed to tell the drug’s whole story, including what happened during the clinical tests, what the ingredients of the drug formulation are, the results of the animal studies, how the drug behaves in the body, and how it is manufactured, processed and packaged. Once approval of an NDA is obtained, the new drug can be legally marketed starting that day in the U.S.
Recently, the FDA has mandated that NDAs submitted electronically should be done in the eCTD format in place of the previous eNDA standard. The transition has been successful with the promise of reduced review times. To date, the FDA has received over 30,000 submissions in the eCTD format (of those, over 8,300 have been related to NDAs)[4] .
Once the application is submitted the FDA will decide if it will get a standard or accelerated review. A standard review implies an FDA decision within about 9 months.
Requirements for similar products
Biologics Biologics include a wide range of medicinal products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues, such as vaccines and many recombinant proteins used in medical treatments are generally approved by FDA via a Biologic License Application (BLA), rather than an NDA. Manufacture of biologics is considered to differ fundamentally from that of less complex chemicals, requiring a somewhat different approval process.
Generic drugs A generic drug is a drug which is produced and distributed without patent protection. The generic drug may still have a patent on the formulation but not on the active ingredient that have already been approved via an NDA submitted by another maker are approved via an Abbreviated New Drug Application An Abbreviated New Drug Application is an application for a US generic drug approval for an existing licensed medication or approved drug (ANDA), which does not require all of the clinical trials normally required for a new drug in an NDA.[5] Most biological drugs, including a majority of recombinant proteins are considered ineligible for an ANDA under current US law.[6] However, a handful of biologic medicines, including biosynthetic insulin Insulin is a hormone that has extensive effects on metabolism and other body functions, such as vascular compliance. Insulin causes cells in the liver, muscle, and fat tissue to take up glucose from the blood, storing it as glycogen in the liver and muscle, and stopping use of fat as an energy source. When insulin is absent , glucose is not taken, growth hormone Growth hormone is a peptide hormone. It stimulates growth and cell reproduction in humans and other animals. It is a 191-amino acid, single-chain polypeptide hormone that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland. Somatotrophin refers to the growth hormone produced, glucagon Glucagon is an important hormone involved in carbohydrate metabolism. Produced by the pancreas, it is released when the glucose level in the blood is low , causing the liver to convert stored glycogen into glucose and release it into the bloodstream. The action of glucagon is thus opposite to that of insulin, which instructs the body's cells to, calcitonin Calcitonin is a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells of the thyroid, and in many other animals in the ultimobranchial body. It acts to reduce blood calcium (Ca2+), opposing the effects of parathyroid hormone (PTH). It has been found in fish, reptiles, birds, and mammals. Its, and hyaluronidase are grandfathered under governance of the Federal Food Drug and Cosmetics Act, which appears to be because these products were already approved when legislation aimed at regulating biotechnology medicines was later passed as part of the Public Health Services Act.
Biologic medicines governed under the Federal Food Drugs and Cosmetics Act has been an area of considerable confusion and dispute for the FDA, because under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, a "generic" need not be an exact duplicate of the brand-name original in order to be approved. In July 2003, the Sandoz generics unit of Norvartis filed, and the FDA accepted, an ANDA for a "follow-on" version of Pfizer's brand-name human growth hormone (Genotropin) that that Sandoz named Omnitrope using the 505(b)(2) pathway. The application was submitted following lengthy discussions with the FDA and contained preclinical, clinical, and comparability data, as well as literature references to the FDA's original decision on Pfizer's Genotropin. But on September 2, 2004, the FDA told Sandoz that the Agency was unable to reach a decision on whether to approve the company's application for Omnitrope. Frustrated with the FDA's failure to give them a decision on Omnitrope, Sandoz then sued the FDA in U.S. District Court in Washington, D.C., citing a statutory requirement that the FDA is required by law to act on drug applications within 180 days. On May 30, 2006, Judge Ricardo Urbina ruled in favor of Sandoz on the Omnitrope case in a very strongly worded opinion, calling the FDA's repeated delays "egregious" writing that there was absolutely no excuse for a delay that was nearing 1,000 days, and effectively ordered the FDA to give the company a response[7]. Following that lawsuit, the FDA approved Omnitrope. With Omnitrope's approval, the FDA stated that the law governing generics permits approvals like Omnitrope's because they aren't technically forbidden, "as long as the current state of science allows the evaluation necessary to support approval," which is what the the FDA wrote in its response to Pfizer's petition against Omnitrope's ANDA. Since then, the Governors of several different states have also petitioned the FDA for guidelines on generic insulin[8].
Medications intended for use in animals Animals are a major group of mostly multicellular, eukaryotic organisms of the kingdom Animalia or Metazoa. Their body plan eventually becomes fixed as they develop, although some undergo a process of metamorphosis later on in their life. Most animals are motile, meaning they can move spontaneously and independently. Most animals are also are submitted to a different center within FDA, the Center for Veterinary Medicine (CVM) in a New Animal Drug Application (NADA). These are also specifically evaluated for their use in food animals and their possible effect on the food from animals treated with the drug.
Medical devices A medical device is a product which is used for medical purposes in patients, in diagnosis, therapy or surgery. If applied to the body, the effect of the medical device is primarily physical, in contrast to pharmaceutical drugs, which exert a biochemical effect. Specific regional definitions of medical device vary slightly as detailed below. The are approved by a variety of methods depending on the class of the device. A Pre-market Application (PMA) largely equivalent to an NDA is required for class III devices, and a 510(k) approval that shows the device is equal to or better than a predicate device already on the market is required for class II devices. Class I medical devices (such as a toothbrush) do not require any approval at all.
References
- ^ Food, Drug, and Cosmetic Act, Section 505; 21 USC 355]
- ^ 21 CFR 201.5: Labeling Requirements for Prescription Drugs and/or Insulin
- ^ "Daily Med: Current Medication Information". http://dailymed.nlm.nih.gov/dailymed/about.cfm. Retrieved on October 10 2007.
- ^ eCTDBlog.com (2008). "FDA, 30,000 eCTDs and Counting!". eCTDBlog.com. http://www.ectdblog.com/2008/07/fda-30000-ectds-and-counting.html. Retrieved on 2008-07-07.
- ^ FDA, CDER Office of Generic Drugs
- ^ Rouhi, A.M. "Beyond Hatch-Waxman: Legislative action seeks to close loopholes in U.S. law that delay entry of generics into the market" Chem & Eng News 80(38):53-59
- ^ Heuser, Stephen, "Ruling budges logjam on generic biotech drugs", International Herald Tribune, April 26, 2006.
- ^ Saul, Stephanie; "Bridling at Insulin's Cost, States Push for Generics"; The New York Times, January 11, 2007.
See also
- Regulation of therapeutic goods The regulation of therapeutic goods, that is drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as is the case in
- Investigational New Drug The United States Food and Drug Administration's Investigational New Drug program is the means by which a pharmaceutical company obtains permission to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved. The FDA reviews the IND application for safety to
- Kefauver Harris Amendment
- Active ingredient An active ingredient , also active pharmaceutical ingredient (API) or bulk active, is the substance in a drug that is pharmaceutically active. The term is similarly used in pesticide formulations where the term active substance is also used. Some medications may contain more than one active ingredient. The traditional word for the API is pharmacon
- Drug development Drug development is a blanket term used to define the entire process of bringing a new drug or device to the Market. It includes Drug discovery / product development, pre-clinical research and Clinical trials (on humans). Few people still refer to the drug developent as mere preclinical development
- Clinical trial In medical research, clinical trials are conducted to allow safety and efficacy data to be collected for new drugs or devices. These trials can only take place once satisfactory information has been gathered on the quality of the product and its non-clinical safety, and Health Authority/Ethics Committee approval is granted in the country where the
- Food and Drug Administration The Food and Drug Administration is an agency of the United States Department of Health and Human Services and is responsible for regulating and supervising the safety of foods, dietary supplements, drugs, vaccines, biological medical products, blood products, medical devices, radiation-emitting devices, veterinary products, and cosmetics. The FDA (FDA)
- European Medicines Agency The European Medicines Agency is a European agency for the evaluation of medicinal products. From 1995 to 2004, the European Medicines Agency was known as The European Agency for the Evaluation of Medicinal Products (EMEA)
- Ministry of Health, Labour and Welfare (Japan) The Ministry of Health, Labour and Welfare is a cabinet level ministry of the Japanese government. It is commonly known as Kōrō-shō (厚労省) in Japan. This ministry provides regulations on maximum residue limits for agricultural chemicals in foods, basic food and drug regulations, standards for foods, food additives, etc
Categories: Pharmacology Pharmacology (in Greek: pharmacon meaning drug, and logos (λόγος) meaning science) is the study of how chemical substances interact with living systems. If substances have medicinal properties, they are considered pharmaceuticals. The field encompasses drug composition and properties, interactions, toxicology, therapy, and medical | Clinical research Categories: Health research | Medical research | Research | Pharmaceutical industry | Food and Drug Administration This category contains articles related to the Food and Drug Administration, an agency of the United States Department of Health and Human Services | Drug safety Categories: Drugs | Product safety | Patient safety | Chemical safety
CNBC
Biegelsen lowered his 2009 sales estimates for Humira, noting the drug "faces near-term headwinds from the economy and new competition from Johnson ...
and more »
Jenny
Wed, 01 Jul 2009 15:54:00 GM
But the media have bought into . drug. company spin that claimed that the underlying depression that required the . drug. use was what caused obesity. This . new. data appears to disprove that claim. Given the current high prescription level of ...
Q. just as if they were applying for a job (which they are) and we were the employers (which we are but have forgotten it). included in this application would be a psychological exam, physical, lie dectector test, drug screening, examination of past and present work history...add any other requirements with your answer that you think would be helpful. this is a non partisan question and would apply to ALL candidates no matter party affilitation. can you imagine how the political climate would change if we base our 'hiring' on the facts alone !
Asked by curiously strong - Tue Nov 7 14:53:59 2006 - - 6 Answers - 0 Comments
A. excellent idea ...but the higher ups will never approve it because it would be their worst nightmare...excellent idea my friend ...simply excellent
Answered by gry w - Tue Nov 7 14:58:49 2006
